Skip to content

Study · Not a test of the peptide alone · 2005

7 results

Short-term testosterone supplementation does not activate GH and IGF-I production in postmenopausal women.

Soares-Welch C, Mielke KL, Bowers CY, Veldhuis JD

Clinical endocrinology1 Jul 2005Cited by 5 (Europe PMC)

PMID15963058 (opens in a new tab)DOI10.1111/j.1365-2265.2005.02294.x (opens in a new tab)PepBankPUB-15963058
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, transdermal testosterone at low and high dose increased serum testosterone versus placebo.

    In plain wordsIn older women, testosterone skin treatment raised blood testosterone compared with placebo.

    Peptide
    GHRP-2
    Outcome
    IncreaseSerum testosterone concentration
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Graded Te supplementation increased serum Te concentrations (nmol/l) from 0.87 +/- 0.06 [Pl] to 5 +/- 1 [low] and 7.3 +/- 1.6 [high] (P < 0.001)
    2 context sentences
    Summary · context
    Placebo (Pl) and a low vs. high dose of Te were administered transdermally for 7 days to each of 15 healthy older women (ages 48-81 years) in a randomized, double-blind crossover design.
    Summary · context
    Frequent blood sampling, GHRP-2 (Growth hormone releasing peptide-2) infusion, and deconvolution analysis were used to assess GH secretion.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, testosterone supplementation did not change pulsatile GH secretion measured with GHRP‑2 infusion.

    In plain wordsIn older women, testosterone did not change pulsatile growth hormone release, which was measured with GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    No significant changePulsatile GH secretion
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    (i) pulsatile GH secretion (microg/l/12 h; conversion factor: 1 microg/l = 0.33 mU/l), 29 +/- 7.2, 32 +/- 5.6 and 27 +/- 4.9
    2 context sentences
    Summary · context
    Placebo (Pl) and a low vs. high dose of Te were administered transdermally for 7 days to each of 15 healthy older women (ages 48-81 years) in a randomized, double-blind crossover design.
    Summary · context
    Frequent blood sampling, GHRP-2 (Growth hormone releasing peptide-2) infusion, and deconvolution analysis were used to assess GH secretion.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, testosterone supplementation did not change GH regularity.

    In plain wordsIn older women, testosterone did not change how regular growth hormone release was.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH regularity (approximate entropy)
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    (ii) GH regularity (approximate entropy), 0.52 +/- 0.05, 0.57 +/- 0.05 and 0.56 +/- 0.05
    2 context sentences
    Summary · context
    Placebo (Pl) and a low vs. high dose of Te were administered transdermally for 7 days to each of 15 healthy older women (ages 48-81 years) in a randomized, double-blind crossover design.
    Summary · context
    Frequent blood sampling, GHRP-2 (Growth hormone releasing peptide-2) infusion, and deconvolution analysis were used to assess GH secretion.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 04HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, testosterone supplementation did not change IGF-I concentrations.

    In plain wordsIn older women, testosterone did not change blood IGF-I levels.

    Peptide
    GHRP-2
    Outcome
    No significant changeIGF-I concentration
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    (iii) IGF-I concentrations (microg/l; conversion factor: 1 microg/l = 0.131 nmol/l), 126 +/- 13, 135 +/- 15 and 141 +/- 13
    2 context sentences
    Summary · context
    Placebo (Pl) and a low vs. high dose of Te were administered transdermally for 7 days to each of 15 healthy older women (ages 48-81 years) in a randomized, double-blind crossover design.
    Summary · context
    Frequent blood sampling, GHRP-2 (Growth hormone releasing peptide-2) infusion, and deconvolution analysis were used to assess GH secretion.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  5. 05HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, testosterone supplementation did not change IGFBP-3.

    In plain wordsIn older women, testosterone did not change blood IGFBP-3 levels.

    Peptide
    GHRP-2
    Outcome
    No significant changeIGFBP-3 concentration
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    (iv) IGFBP-3 (mg/l), 3.7 +/- 0.2, 3.6 +/- 0.1 and 3.7 +/- 0.2
    2 context sentences
    Summary · context
    Placebo (Pl) and a low vs. high dose of Te were administered transdermally for 7 days to each of 15 healthy older women (ages 48-81 years) in a randomized, double-blind crossover design.
    Summary · context
    Frequent blood sampling, GHRP-2 (Growth hormone releasing peptide-2) infusion, and deconvolution analysis were used to assess GH secretion.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  6. 06HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, testosterone supplementation did not change IGFBP-1.

    In plain wordsIn older women, testosterone did not change blood IGFBP-1 levels.

    Peptide
    GHRP-2
    Outcome
    No significant changeIGFBP-1 concentration
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    (v) IGFBP-1 (microg/l), 41 +/- 2.3, 44 +/- 3.8 and 44 +/- 3.2
    2 context sentences
    Summary · context
    Placebo (Pl) and a low vs. high dose of Te were administered transdermally for 7 days to each of 15 healthy older women (ages 48-81 years) in a randomized, double-blind crossover design.
    Summary · context
    Frequent blood sampling, GHRP-2 (Growth hormone releasing peptide-2) infusion, and deconvolution analysis were used to assess GH secretion.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  7. 07HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome

    In healthy postmenopausal women, testosterone supplementation did not change the mass of GH secreted after GHRP‑2 injection.

    In plain wordsIn older women, testosterone did not change how much growth hormone was released after a GHRP‑2 injection.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH mass secreted after GHRP-2 injection
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    (vi) the mass of GH secreted (microg/l/3 h) after GHRP-2 injection, 123 +/- 27, 146 +/- 32 and 147 +/- 38
    2 context sentences
    Summary · context
    Placebo (Pl) and a low vs. high dose of Te were administered transdermally for 7 days to each of 15 healthy older women (ages 48-81 years) in a randomized, double-blind crossover design.
    Summary · context
    Frequent blood sampling, GHRP-2 (Growth hormone releasing peptide-2) infusion, and deconvolution analysis were used to assess GH secretion.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.